FindTrial
Sign In

Comprehensive Diagnosis and Treatment for Meibomian Gland Dysfunction Using New Technology

Comprehensive Diagnosis and Treatment for Meibomian Gland Dysfunction Using New Technology

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-DDD-16009891
Enrollment
Unknown
Registered
2016-11-17
Start date
2016-12-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Meibomian Gland Dysfunction

Interventions

Gold Standard:
Index test:

Sponsors

Shanghai First People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 80 years; 2. OSDI score > 12; 3. Complete the informed consent.

Exclusion criteria

Exclusion criteria: 1. Pregnant or breastfeeding woman; 2. Any co-existing ocular conditions that could interfere with dry eye (e.g. use of systemic antihistamines, anti-inflammatory drugs, or corticosteroids).

Design outcomes

Primary

MeasureTime frame
LLT;Shape of meibomian gland acinar;concentration of cytokine;—

Secondary

MeasureTime frame
OSDI;SPEED;BUT;TMH;—

Countries

China

Contacts

Public ContactBilian Ke

Shanghai First People's Hospital

kebilian@126.com+86 13386259873

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026